FiggyPiggy, We agree that International Fusion is
Post# of 30028
Posted On: 09/08/2016 11:21:06 AM
Re: FiggyPiggy #23927
FiggyPiggy,
We agree that International Fusion is a joke, (I spoke to Jeff Stephens in January and let's just say I was not impressed.), but I have to respectfully disagree with your idea about financing being the holdup. They don't have any more assets today than a year ago, so I don't see AMBS being able to get any kind of favorable financing at this point that they wouldn't have already been able to get during the last 12 months. (It may be possible that the partner is doing an offering on their end to come up with the money for a deal, but hopefully they are strong enough they don't need to.)
I think the most likely scenario is they are waiting on an action from the FDA- either having to do with the Orphan Drug Designation or the Rare Ped Disease Designation, and/or the retraining. The regulatory process to get ESS approved impacts the cost to develop it and it's current value.
They may very well end up doing a R/S- I never said it was only for negotiation tactics. What I meant was they needed to have a plan if they were unable to bring on a partner and even if they do, depending on what the terms are, they may very well still do the R/S, but they can then decide what the ratio will be. And in so doing, a partner sees that they are preparing for all contingencies, even if the partner walks. As Fred emailed me, they are "staying the course until a deal is finalized."
You stated:
"Last I heard they sold out on the manufactured run to 1.40...I have not confirmed this though" What are you referring to?
We agree that International Fusion is a joke, (I spoke to Jeff Stephens in January and let's just say I was not impressed.), but I have to respectfully disagree with your idea about financing being the holdup. They don't have any more assets today than a year ago, so I don't see AMBS being able to get any kind of favorable financing at this point that they wouldn't have already been able to get during the last 12 months. (It may be possible that the partner is doing an offering on their end to come up with the money for a deal, but hopefully they are strong enough they don't need to.)
I think the most likely scenario is they are waiting on an action from the FDA- either having to do with the Orphan Drug Designation or the Rare Ped Disease Designation, and/or the retraining. The regulatory process to get ESS approved impacts the cost to develop it and it's current value.
They may very well end up doing a R/S- I never said it was only for negotiation tactics. What I meant was they needed to have a plan if they were unable to bring on a partner and even if they do, depending on what the terms are, they may very well still do the R/S, but they can then decide what the ratio will be. And in so doing, a partner sees that they are preparing for all contingencies, even if the partner walks. As Fred emailed me, they are "staying the course until a deal is finalized."
You stated:
"Last I heard they sold out on the manufactured run to 1.40...I have not confirmed this though" What are you referring to?
(1)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼